Major Depressive Disorder

Latest News

depression
New Phase 3 Study Results on Lumateperone, An Adjunctive Therapy to Antidepressants

April 16th 2024

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints of a new phase 3 study.

From a look at record-high suicide rates to subspecialty shortages in psychiatry, here are highlights from the week in Psychiatric Times.
The Week in Review: April 8-12

April 13th 2024

From a groundbreaking FDA approval to the hidden toll of COVID-19, here are highlights from the week in Psychiatric Times.
The Week in Review: April 1-5

April 6th 2024

“The selectivity of NBI-1070770 for the NMDA NR2B receptor may benefit patients with moderate to severe depression.”
First Patient Dosed in Phase 2 Clinical Trial of NBI-1070770 for MDD

April 3rd 2024

MDD
ALTO-203 for Major Depressive Disorder and Anhedonia: Phase 2 Study Initiated

April 3rd 2024

Latest CME Events & Activities

The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease

View More

Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis

View More

Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia

View More

Advances In™ Schizophrenia: Expanding the Therapeutic Landscape

View More

Southern California Psychiatry Conference

September 13-14, 2024

Register Now!

Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder

View More

5th Annual International Congress on the Future of Neurology®

View More

2023 Annual Psychiatric Times™ World CME Conference

View More

Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II

View More

Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments

View More

Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies

View More

'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care

View More

More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression

View More

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

More News

© 2024 MJH Life Sciences

All rights reserved.